All In MedTech

FDA Clearance Tracker · P040045-S001

VISTAKON (SENOFILCON A) CONTACT LENS MATERIAL

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 14, 2007 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 14, 2007

Approved

Time to decision

113 days

Received Apr 23, 2007. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P040045-S001
Device name
VISTAKON (SENOFILCON A) CONTACT LENS MATERIAL
Applicant location
Jacksonville, FL
Received
Apr 23, 2007
Decided
Aug 14, 2007
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P040045

Device type

Device class
Class III
Regulation
21 CFR 886.5925
Specialty
Ophthalmology

Every decision under product code LPM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR AN ADDITIONAL INDICATION FOR THERAPEUTIC USE FOR THE VISTAKON (SENOFILCON A) CONTACT LENS. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME ACUVUE OASYS BRAND CONTACT LENSES WITH HYDRACLEAR PLUS (SENOFILCON A) AND IS ADDITIONALLY INDICATED FOR THERAPEUTIC USE AS A BANDAGE LENS FOR THE FOLLOWING ACUTE AND CHRONIC CONDITIONS:1) FOR CORNEAL PROTECTION IN LID AND CORNEAL ABNORMALITIES SUCH AS ENTROPION, TRICHIASIS, TARSAL SCARS AND RECURRENT CORNEAL EROSION. IN ADDITION IT IS INDICATED FOR PROTECTION WHERE SUTURES OR OCULAR STRUCTURE MALFORMATION, DEGENERATION OR PARALYSIS MAY RESULT IN THE NEED TO PROTECT THE CORNEA FROM EXPOSURE OR REPEATED IRRITATION. 2) FOR CORNEAL PAIN RELIEF IN CONDITIONS SUCH AS BULLOUS KERATOPATHY, EPITHELIAL EROSION AND ABRASION, FILAMENTARY KERATITIS, AND POST-KERATOPLASTY. 3) FOR USE AS A BARRIER DURING THE HEALING PROCESS OF EPITHELIAL DEFECTS SUCH AS CHRONIC EPITHELIAL DEFECTS, CORNEAL ULCER, NEUROTROPHIC AND NEUROPARALYTIC KERATITIS, AND CHEMICAL BURNS. 4) FOR POST SURGICAL CONDITIONS WHERE BANDAGE LENS USE IS INDICATED SUCH AS POST REFRACTIVE SURGERY, LAMELLAR GRAFTS, CORNEAL FLAPS, AND ADDITIONAL OCULAR SURGICAL CONDITIONS. 5) FOR STRUCTURAL STABILITY AND PROTECTION IN PIGGY BACK LENS FITTING WHERE THE CORNEA AND ASSOCIATED SURFACES ARE TOO IRREGULAR TO ALLOW FOR CORNEAL RIGID GAS PERMEABLE (RGP) LENSES TO BE FIT. IN ADDITION THE USE OF THE LENS CAN PREVENT IRRITATION AND ABRASIONS IN CONDITIONS WHERE THERE ARE ELEVATION DIFFERENCES IN THE HOST/GRAPH JUNCTION OR SCAR TISSUE. LENSES PRESCRIBED FOR THERAPEUTIC USE MAY BE WORN FOR DAILY OR EXTENDED WEARING PERIODS.

Source documents

Other decisions for Vistakon, Division of Johnson & Johnson Vision Car

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.